Pharmafile Logo

News and Press Releases

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...

Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024

Relation
enquiry@relationrx.com
Regent’s Place 338 Euston Road London NW1 3BG

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

5 November 2024 –Tokyo, Japan and London and Cardiff, UK – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio...

Category: BioManufacturing
Posted: November 6, 2024

Nxera Pharma
Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 17, 2024

AC Immune
info@acimmune.com
EPFL Innovation Park-Building B 1015 Lausanne / Switzerland

Asceneuron Secures $100m Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK...

Category: Biotechnology, Clinical Trials, Other
Posted: July 16, 2024

Asceneuron SA
asce-contact@asceneuron.com
Asceneuron SA, EPFL Innovation Park, Bâtiment B, CH-1015 Lausanne, Switzerland

Nxera Pharma Receives US$10m from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

27 June 2024, Tokyo, Japan and Cambridge, UK - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...

Category: BioManufacturing, Other, Pharmaceutical
Posted: June 28, 2024

Nxera Pharma
Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024

Allyx Therapeutics
info@allyxthera.com
555 Long Wharf Drive Floor 11 New Haven, CT 06511, US

Pharma and Regulatory Giants Tackle AI Trust and Legislative Challenges at Largest Ever Pistoia Alliance Annual Conference

Survey of life sciences experts found 70% recognise potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and...

Category: Clinical Trials, Logistics
Posted: May 8, 2024

The Pistoia Alliance
info@pistoiaalliance.org
401 Edgewater Pl, Wakefield, Massachusetts, US

Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial

Treatment for rare childhood disease was well tolerated and slowed loss of motor function 20 March 2024 -- Maryland, US -- An investigational gene therapy for a rare neurodegenerative disease...

Category: Clinical Trials, Drug Discovery
Posted: March 20, 2024

National Institute of Health (NIH)
olib@od.nih.gov
9000 Rockville Pike Bethesda, Maryland 20892